Quinoxaline Compounds Targeting Eg5 Motor Protein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and other proliferative diseases often target tubulin, affecting normal cellular processes and microtubules, leading to a need for small molecules that specifically target proteins associated with proliferating cells without disrupting normal cellular functions.
Innovation Solution
Development of quinoxaline compounds that inhibit cell proliferation and induce apoptosis by targeting the Eg5 motor protein, disrupting the mitotic spindle and causing cell cycle arrest, thereby inhibiting tumor growth and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tubulin binding agents are used to arrest cells in mitosis, then anti-tumor activity is improved, but normal cellular processes are adversely affected
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the Eg5 motor protein at a localized functional site within the cell division process. The quinoxaline compounds bind to Eg5 with high specificity, disrupting only the mitotic spindle function while leaving other microtubule-dependent cellular processes intact. This selective targeting resolves the contradiction by improving anti-tumor activity through precise mitotic arrest while minimizing harm to normal cellular functions that rely on microtubules.
Solution Approach 2:
The patent segments the target from the general microtubule system by focusing specifically on the Eg5 motor protein rather than tubulin itself. This segmentation allows the compound to interfere with a specific component of the mitotic machinery (Eg5-mediated spindle bipolarity) without affecting other tubulin functions. The approach divides the broad anti-mitotic effect into a targeted action against a single protein, thereby improving therapeutic selectivity and reducing off-target effects on normal cells.
2Reliability
If small molecules target proteins with essential functions in mitosis, then cell cycle arrest is improved, but specificity to proliferating cells is reduced
Solution Approach 1:
The quinoxaline compounds exhibit local quality by targeting Eg5, a protein that is overexpressed or hyperactive specifically in proliferating and cancerous cells. The compounds bind to Eg5 with high affinity and specificity, inducing cell cycle arrest in mitosis primarily in rapidly dividing cells. This selective targeting improves cell cycle arrest efficacy in tumor cells while sparing normal, non-proliferating cells, thereby resolving the contradiction between reliable cell cycle arrest and specificity to proliferating cells.
Solution Approach 2:
The patent employs parameter changes by exploiting the differential expression and activity levels of Eg5 in proliferating versus non-proliferating cells. Cancer cells typically exhibit elevated Eg5 expression or activity, making them more sensitive to Eg5 inhibition. The quinoxaline compounds leverage this parameter difference (Eg5 activity level) to achieve selective cell cycle arrest in proliferating cells. By targeting a protein whose functional state differs between normal and cancerous cells, the invention improves both cell cycle arrest reliability and cellular specificity.
Data Source
AI summary
The present invention generally relates to quinoxaline compounds having Formula 1 or Formula 2 wherein the variables are as defined herein, and methods of using them.